CHICAGO, AUGUST 25, 2020 — The Clinical trials investigating 16 promising therapies for Alzheimer’s and dementia are taking off thanks to $24 million in new grant funding from the Alzheimer’s Association’s Part the Cloud global research grant program and Bill Gates. Read Full Press Release Here
T3D Therapeutics is a North Carolina-based biotechnology company that develops novel therapeutics for the treatment of Alzheimers and neurological disorders.